Adjuvant chemotherapy for locally advanced cervical cancer - Authors' reply

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne 3000, VIC, Australia. Electronic address: linda.mileshkin@petermac.org.
² University of Melbourne, Melbourne, VIC, Australia.
³ Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
⁴ NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
⁵ HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA.

Comment

Linda R Mileshkin et al. Lancet Oncol. 2023 Jul.

. 2023 Jul;24(7):e290.

doi: 10.1016/S1470-2045(23)00294-2.

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne 3000, VIC, Australia. Electronic address: linda.mileshkin@petermac.org.
² University of Melbourne, Melbourne, VIC, Australia.
³ Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
⁴ NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
⁵ HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA.

No abstract available

Conflict of interest statement

Declarations of interest are unchanged from the published Article.

Adjuvant chemotherapy for locally advanced cervical cancer.
Sari SY, Akdag NNS, Gultekin M, Yildiz F. Sari SY, et al. Lancet Oncol. 2023 Jul;24(7):e289. doi: 10.1016/S1470-2045(23)00270-X. Lancet Oncol. 2023. PMID: 37414017 No abstract available.